Literature DB >> 30489648

Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI.

Lin Chen1,2,3, Jun Hua2,3, Christopher A Ross4,5, Shuhui Cai1, Peter C M van Zijl2,3, Xu Li2,3.   

Abstract

Altered brain iron content in the striatum of premanifest and manifest Huntington's disease (HD) has been reported. However, its natural history remains unclear. This study aims to investigate altered brain iron content in premanifest and early HD, and the iron deposition rate in these patients through a longitudinal one-year follow-up test, with quantitative magnetic susceptibility as an iron imaging marker. Twenty-four gene mutation carriers divided into three groups (further-from-onset, closer-to-onset and early HD) and 16 age-matched healthy controls were recruited at baseline, and of these, 14 carriers and 7 controls completed the one-year follow-up. Quantitative magnetic susceptibility and effective transverse relaxation rate ( R 2 ∗ ) were measured at 7.0 Tesla and correlated with atrophy and available clinical and cognitive measurements. Higher susceptibility values indicating higher iron content in the striatum and globus pallidus were only observed in closer-to-onset (N = 6, p < 0.05 in caudate and p < 0.01 in putamen) and early HD (N = 9, p < 0.05 in caudate and globus pallidus and p < 0.01 in putamen). Similar results were found by R 2 ∗ measurement. Such increases directly correlated with HD CAG-age product score and brain atrophy, but not with motor or cognitive scores. More importantly, a significantly higher iron deposition rate (11.9%/years in caudate and 6.1%/years in globus pallidus) was firstly observed in closer-to-onset premanifest HD and early HD as compared to the controls. These results suggest that monitoring brain iron may provide further insights into the pathophysiology of HD disease progression, and may provide a biomarker for clinical trials.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Huntington’s disease; QSM; brain atrophy; brain iron deposition; cross-sectional study; longitudinal study

Year:  2018        PMID: 30489648      PMCID: PMC6367012          DOI: 10.1002/jnr.24358

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  62 in total

Review 1.  Basal ganglia and cerebellar loops: motor and cognitive circuits.

Authors:  F A Middleton; P L Strick
Journal:  Brain Res Brain Res Rev       Date:  2000-03

2.  Quantitative neuropathological changes in presymptomatic Huntington's disease.

Authors:  E Gómez-Tortosa; M E MacDonald; J C Friend; S A Taylor; L J Weiler; L A Cupples; J Srinidhi; J F Gusella; E D Bird; J P Vonsattel; R H Myers
Journal:  Ann Neurol       Date:  2001-01       Impact factor: 10.422

Review 3.  Imaging iron stores in the brain using magnetic resonance imaging.

Authors:  E Mark Haacke; Norman Y C Cheng; Michael J House; Qiang Liu; Jaladhar Neelavalli; Robert J Ogg; Asadullah Khan; Muhammad Ayaz; Wolff Kirsch; Andre Obenaus
Journal:  Magn Reson Imaging       Date:  2005-01       Impact factor: 2.546

4.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

Review 5.  Iron, brain ageing and neurodegenerative disorders.

Authors:  Luigi Zecca; Moussa B H Youdim; Peter Riederer; James R Connor; Robert R Crichton
Journal:  Nat Rev Neurosci       Date:  2004-11       Impact factor: 34.870

6.  Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test.

Authors:  B A Parmenter; B Weinstock-Guttman; N Garg; F Munschauer; R H B Benedict
Journal:  Mult Scler       Date:  2007-01       Impact factor: 6.312

7.  Onset and rate of striatal atrophy in preclinical Huntington disease.

Authors:  E H Aylward; B F Sparks; K M Field; V Yallapragada; B D Shpritz; A Rosenblatt; J Brandt; L M Gourley; K Liang; H Zhou; R L Margolis; C A Ross
Journal:  Neurology       Date:  2004-07-13       Impact factor: 9.910

8.  Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications.

Authors:  George Bartzokis; Po H Lu; Todd A Tishler; Sophia M Fong; Bolanle Oluwadara; J Paul Finn; Danny Huang; Yvette Bordelon; Jim Mintz; Susan Perlman
Journal:  Neurochem Res       Date:  2007-05-05       Impact factor: 3.996

Review 9.  Fast robust automated brain extraction.

Authors:  Stephen M Smith
Journal:  Hum Brain Mapp       Date:  2002-11       Impact factor: 5.038

10.  Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles.

Authors:  P Hilditch-Maguire; F Trettel; L A Passani; A Auerbach; F Persichetti; M E MacDonald
Journal:  Hum Mol Genet       Date:  2000-11-22       Impact factor: 6.150

View more
  10 in total

1.  Sex-specific differences in rim appearance of multiple sclerosis lesions on quantitative susceptibility mapping.

Authors:  Tolaymat B; Zheng W; Chen H; Choi S; Li X; Harrison Dm
Journal:  Mult Scler Relat Disord       Date:  2020-06-18       Impact factor: 4.339

2.  QSMxT: Robust masking and artifact reduction for quantitative susceptibility mapping.

Authors:  Ashley Wilton Stewart; Simon Daniel Robinson; Kieran O'Brien; Jin Jin; Georg Widhalm; Gilbert Hangel; Angela Walls; Jonathan Goodwin; Korbinian Eckstein; Monique Tourell; Catherine Morgan; Aswin Narayanan; Markus Barth; Steffen Bollmann
Journal:  Magn Reson Med       Date:  2021-10-22       Impact factor: 4.668

Review 3.  Early differentiation of neurodegenerative diseases using the novel QSM technique: what is the biomarker of each disorder?

Authors:  Farzaneh Nikparast; Zohreh Ganji; Hoda Zare
Journal:  BMC Neurosci       Date:  2022-07-28       Impact factor: 3.264

Review 4.  The Key Role of Magnetic Resonance Imaging in the Detection of Neurodegenerative Diseases-Associated Biomarkers: A Review.

Authors:  Ke-Ru Li; An-Guo Wu; Yong Tang; Xiao-Peng He; Chong-Lin Yu; Jian-Ming Wu; Guang-Qiang Hu; Lu Yu
Journal:  Mol Neurobiol       Date:  2022-07-12       Impact factor: 5.682

5.  Single-step calculation of susceptibility through multiple orientation sampling.

Authors:  Lin Chen; Shuhui Cai; Peter C M van Zijl; Xu Li
Journal:  NMR Biomed       Date:  2021-04-06       Impact factor: 4.478

6.  Altered iron and myelin in premanifest Huntington's Disease more than 20 years before clinical onset: Evidence from the cross-sectional HD Young Adult Study.

Authors:  Eileanoir B Johnson; Christopher S Parker; Rachael I Scahill; Sarah Gregory; Marina Papoutsi; Paul Zeun; Katherine Osborne-Crowley; Jessica Lowe; Akshay Nair; Carlos Estevez-Fraga; Kate Fayer; Geraint Rees; Hui Zhang; Sarah J Tabrizi
Journal:  EBioMedicine       Date:  2021-03-08       Impact factor: 8.143

7.  Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31.

Authors:  Danielle A Simmons; Brian D Mills; Robert R Butler Iii; Jason Kuan; Tyne L M McHugh; Carolyn Akers; James Zhou; Wassim Syriani; Maged Grouban; Michael Zeineh; Frank M Longo
Journal:  Neurotherapeutics       Date:  2021-03-30       Impact factor: 7.620

8.  Ironsmith: An automated pipeline for QSM-based data analyses.

Authors:  Valentinos Zachariou; Christopher E Bauer; David K Powell; Brian T Gold
Journal:  Neuroimage       Date:  2021-12-20       Impact factor: 6.556

Review 9.  Novel insights into ferroptosis: Implications for age-related diseases.

Authors:  Ren-Peng Zhou; Yong Chen; Xin Wei; Bin Yu; Zhi-Gang Xiong; Chao Lu; Wei Hu
Journal:  Theranostics       Date:  2020-10-26       Impact factor: 11.556

10.  Iron Deposition in Gray Matter Nuclei of Patients With Intracranial Artery Stenosis: A Quantitative Susceptibility Mapping Study.

Authors:  Huimin Mao; Weiqiang Dou; Xinyi Wang; Kunjian Chen; Xinyu Wang; Yu Guo; Chao Zhang
Journal:  Front Neurol       Date:  2022-01-05       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.